[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphedema-lower-limb\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphedema-lower-limb":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,88,120,141,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100638885","extracorporeal-shock-wave-therapy-in-lower-extremity-lymphedema-100638885",false,"NCT07626645","Extracorporeal Shock Wave Therapy in Lower Extremity Lymphedema","Efficacy of Extracorporeal Shock Wave Therapy (ESWT) in Lower Extremity Lymphedema: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 to 80 years\n* Clinical diagnosis of lower extremity lymphedema established at least 6 months prior to enrollment\n* Completion of at least one cycle of CDT Phase 1 (intensive decongestive phase) within the preceding six months\n* Currently in CDT Phase 2 (maintenance phase) with active use of compression garments\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Active chemotherapy or radiotherapy\n* Active infection\n* Lower extremity vascular diseases including deep vein thrombosis or arterial insufficiency\n* Presence of a cardiac pacemaker\n* Pregnancy\n* Bleeding disorders","ALL","18 Years","80 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"NA","Lower extremity lymphedema is a chronic and progressive condition associated with significant functional impairment and reduced quality of life. The current gold-standard treatment is Complex Decongestive Therapy (CDT); however, a substantial proportion of patients continue to experience persistent symptoms during the maintenance phase. This prospective, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effectiveness of Extracorporeal Shock Wave Therapy (ESWT) as an adjunct to standard CDT maintenance therapy in patients with lower extremity lymphedema. Participants will be randomly allocated to either an active ESWT group or a sham ESWT group, with both groups continuing standard CDT maintenance throughout the study. ESWT will be administered twice weekly for five sessions. Changes in limb volume, skin thickness and subcutaneous tissue thickness assessed by ultrasonography, pain, functional status, and quality of life will be evaluated at baseline, after treatment, and at one-month follow-up.",[27,28,29,30,31],"Lymphedema, Lower Limb","Extracorporeal Shock Wave Therapy","Edema Leg","Sham-controlled","Placebo Control Design",[33,34,35,36,37,38,39],"Lower Extremity Lymphedema","Extracorporeal Shock Wave Therapy (ESWT)","Complex Decongestive Therapy (CDT)","Limb Volume","Ultrasonography","skin and subcutaneous tissue thickness","Quality of Life","NOT_YET_RECRUITING","2026-06-02",{"date":43,"type":44},"2026-06-04","ACTUAL",{"date":46,"type":21},"2026-06-22",{"date":48,"type":21},"2027-02-01",{"name":50,"class":51},"Gazi University","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":52},"100631299","detecting-the-undetected-heart-failure-screening-at-the-lymphoedema-point-of-care-100631299","NCT07498868","Detecting the Undetected: Heart Failure Screening at the Lymphoedema Point of Care","Detecting the Undetected: an Observational Cohort Study Evaluating the Health Economics, Clinical Utility, and Patient and Staff Experiences of Innovative Peptide Testing to Screen for Heart Failure in Lymphoedema Clinics","Inclusion Criteria:\n\n* Patient of Swansea Bay University Health Board Lymphoedema Service.\n* Consent to participate in the study.\n* Bilateral lower limb oedema.\n* Aged 18-years or older.\n* Able to provided informed consent to be involved.\n* No diagnosis of heart failure.\n* No NT-proBNP test in the previous 12-months OR increase in lymphoedema severity since an NT-proBNP test in the last 12-months.\n\nExclusion Criteria:\n\n* All inclusion criteria not met.\n* Not a lymphoedema patient in Swansea Bay University Health Board Lymphoedema Service.\n* Unable to consent for themselves.\n* Women who are pregnant or have given birth in the last 6-months.\n* Patients with an existing heart failure diagnosis.",{"count":61,"type":21},618,"OBSERVATIONAL","Heart failure affects more people than the four most common cancers combined. When identified early, management is more straightforward, preventing complications, hospitalisations, and fatalities. Breathlessness and fatigue are cardinal symptoms of heart failure that can present in a number of conditions. As a result, leg swelling, the third cardinal symptom, is the first noted in many people. The presence of leg swelling leads to patients being seen in lymphoedema clinics before the need for cardiology investigation has been identified. Lymphoedema is the presence of chronic oedema as a result of congenital abnormalities, inflammation, infection, trauma, or cancer and its treatments. The vast majority of lymphoedema patients have swelling in their legs.\n\nA recent study has shown that 9.4% lymphoedema patients need to be investigated for heart failure. At present, the need for investigation is identified by performing a laboratory blood test, which takes time to arrange and complete. An alternate point of care test can provide a result in 12-minutes at the lymphoedema appointment, and enable appropriate action to be taken. This can reduce the demands on primary care and shorten the chain of events to a specialist assessment, as well as reducing inappropriate referrals.\n\nThis research, funded by NHS Wales Performance and Improvement, will perform a point of care test to screen for possible heart failure in lymphoedema clinics and establish the clinical utility by exploring the experiences of patients and staff involved and determining the health economic benefits. A supplementary aim is to compare the point of care test to the currently used laboratory test in a subsample to promote confidence in the test and support efforts to spread and scale across all health boards in Wales on completion.",[27,65,66,67,68],"Lymphedema","Heart Failure","Heart Failure (for Example, Fluid Overload)","Heart Failure (HF)",[70,71,72,73,74,75,76,77,78],"lymphoedema","heart failure","undetected heart failure","undiagnosed heart failure","bilateral lower limb oedema","bilateral leg oedema","point of care testing","screening","NT-proBNP","2026-03-23",{"date":81,"type":44},"2026-03-27",{"date":83,"type":21},"2026-05",{"date":85,"type":21},"2028-09",{"name":87,"class":51},"Swansea Bay University Health Board",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":98,"conditions":99,"keywords":104,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":119},"100522417","the-n-lva-study-rct-comparing-lva-vs-sham-surgery-in-cancer-related-lymphedema-100522417","NCT06082349","The N-LVA Study: RCT Comparing LVA vs. Sham Surgery in Cancer-related Lymphedema","Effectiveness and Cost-effectiveness of Lymphaticovenous Anastomosis for Cancer Patients Who Suffer From Chronic Peripheral Lymphedema: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Treated for cancer and underwent treatment of either axillary or inguinal lymph nodes or radiotherapy;\n* Early stage lymphedema (ISL I-II) in the upper or lower extremity, and diagnosed by lymphoscintigraphy for the lower extremity;\n* Unilateral lymphedema;\n* Viable lymphatic vessels as determined by indocyanine green (ICG)Lymphography (stage II-III);\n* Refractory lymphedema that underwent at least three months of conservative treatment;\n* Informed consent.\n\nExclusion Criteria:\n\n* History of lymphatic reconstruction in the past 10 years;\n* Late-stage lymphedema of the extremity (ISL classification ≥ II lymphedema) with evident fat deposition and\u002For fibrosis;\n* Patients with active distant metastases, treated with palliative intent;\n* Patients with the active treatment of primary cancer, i.e. surgery, radiotherapy, and\u002For chemotherapy. Note: patients receiving adjuvant targeted and\u002For endocrine treatment are eligible;\n* Edema due to venous insufficiency, evaluated by venous duplex ultrasound of the deep and superficial venous system;\n* Active infection in the lymphedematous extremity;\n* Bilateral lymphedema;\n* Lymphedema present in genital or breast area only;\n* Primary lymphedema;\n* Non-viable lymphatic system as determined by ICG Lymphography (stages IV and V).",{"count":96,"type":21},110,[24],"The goal of this randomized controlled trial is to compare the effectiveness and cost-effectiveness of lymphaticovenous anastomosis (LVA) with sham surgery for patients suffering from unilateral cancer-related lymphedema in either the upper or lower extremity. It aims to answer whether LVA is more effective than sham surgery in terms of improvement in Lymph-ICF score.\n\nA total of 110 participants will be allocated randomly into two groups at a 1:1 ratio. The first group will receive lymphaticovenous anastomosis (LVA), while the second group will undergo sham surgery.",[100,101,27,102,103],"Lymphedema, Secondary","Lymphedema of Upper Limb","Lymphedema Arm","Lymphedema of Leg",[105,106,107,108],"Lymphaticovenous anastomosis","Sham surgery","Microsurgery","LVA","RECRUITING","2026-01-15",{"date":112,"type":44},"2026-01-16",{"date":114,"type":44},"2023-12-18",{"date":116,"type":21},"2029-03-01",{"name":118,"class":51},"Maastricht University Medical Center",3,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":52},"100551026","shock-wave-therapy-for-lower-limb-lymphedema-100551026","NCT06454734","Shock Wave Therapy for Lower Limb Lymphedema","Lower Limb Lymphedema Treatment by Extracorporeal Shock Wave Therapy: Clinical Trial","Inclusion criteria\n\n* Patients with lower limb lymphedema\n* Lymphedema of at least 6 months of evolution\n* The lymphedema must affect at least the knee to the foot\n* Moderate or severe lymphedema (grades 2 or 3)\n* Sign the informed consent\n\nExclusion criteria\n\n* Under 18 years of age\n* Coagulation disorders (hemophilia, treatment with acenocoumarol, etc.)\n* Current or previous deep vein thrombosis of the lower extremity\n* Pregnancy\n* Electronic implantable medical devices as pacemaker implants, medication pumps, etc\n* Having received treatment with complex decongestive therapy or shock waves during the last 6 months\n* Treatment with corticosteroids or radiotherapy in the area to be treated in the last 6 weeks\n* Active oncological disease in the area to be treated\n* Active infectious-inflammatory process in the area to be treated\n* Cognitive or sensory deficits that prevent collaboration\n* Inability to walk independently or inability to attend therapy",{"count":128,"type":21},30,[24],"This is a double-blind randomized clinical trial to compare the effect of shock wave therapy on lower limb lymphedema. There are two arms: A) complex decongestive therapy + extracorporeal shock waves therapy; B) complex decongestive therapy plus placebo extracorporeal shock waves.",[27],"2025-07-30",{"date":134,"type":44},"2025-07-31",{"date":136,"type":44},"2024-05-28",{"date":138,"type":21},"2026-12",{"name":140,"class":51},"Parc de Salut Mar",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100557997","the-effect-of-dynamic-neuromuscular-stabilization-exercises-in-patients-with-lower-extremity-lymphedema-100557997","NCT06545383","The Effect of Dynamic Neuromuscular Stabilization Exercises in Patients With Lower Extremity Lymphedema","The Effect of Dynamic Neuromuscular Stabilization Exercises on Balance, Proprioception and Functional Level in Patients With Lower Extremity Lymphedema","Inclusion Criteria:\n\n* Being 18 years or older\n* Being diagnosed with lymphedema due to primary or secondary causes in the lower extremity\n* Having progressed to Complex Decongestive Treatment Phase 2\n* Volunteering to participate in research\n\nExclusion Criteria:\n\n* No mental or cognitive problems\n* Not receiving any other concurrent conservative or surgical treatment during the study.\n* Presence of metastatic cancer\n* Having a neurological disorder that may affect balance or an orthopedic disorder that may prevent walking\n* Presence of active infection in the affected limb\n* Uncontrolled hypertension, presence of serious cardiovascular system disease\n* There is a risk of deep vein thrombosis\n* Presence of open skin wound\n* Having a history of falling in the last 3 months","65 Years",{"count":150,"type":21},42,[24],"After lower extremity lymphedema, individuals physical activity levels and functionality remain very low. This decrease can cause balance problems over time. Surgical and medical treatments reduce the nerve conduction efficiency of the nervous system and negatively affect proprioception, which is the perception of the joint's position in space during movement. Increasing errors in joint position sense reduce control of movement and restrict active movement, which lead to an assumption that balance could be affected. Joint position sense and balance may be negatively affected, causing injuries, and injuries may cause damage to ligaments and sensory nerve fibers. The main aim of the Dynamic Neuromuscular Stabilization (DNS) approach is to restore physiological movement patterns. By activating the deep stabilizer system with DNS exercises, joint movements could improved, and exercise positions will have positive effects on the quality of sensory perception. In addition, positive effects on balance are expected due to decrease in joint position sense errors. Therefore, the aim of the study is to investigate\u002Funderstand the effect of DNS exercises on balance, proprioception and functional level in patients with lower extremity lymphedema. This study will provide information for researchers, therapists, and patients by determining the effectiveness of DNS exercises in patients with lower extremity lymphedema.\n\nfrom Bezmiâlem Vakıf University Faculty of Medicine, Department of Physical Therapy and Rehabilitation, who have been diagnosed with lymphedema due to primary or secondary causes and have progressed to the Complex Decongestive Treatment Phase 2, will constitute the population of the study. The study will be carried out at Istanbul University-Cerrahpaşa Department of Physiotherapy and Rehabilitation.\n\nThe study will consist of two groups. Both groups will be included in an exercise program consisting of breathing exercises, active joint range of motion exercises and walking training. Exercises will be given as a home program for 6 weeks, 3 days a week, 45 minutes a day. Additionally, patients in the Control group will be asked to walk for 40 minutes 2 days a week for 6 weeks. In the intervention group, they will additionally be included in a program consisting of individualized DNS exercises for 40 minutes a day, 2 days a week for 6 weeks. All patients will be asked to wear compression garments during exercises.",[27],[33,155],"Exercise","2024-08-07",{"date":158,"type":44},"2024-08-09",{"date":160,"type":21},"2024-08-01",{"date":162,"type":21},"2025-02-01",{"name":164,"class":51},"Istanbul University - Cerrahpasa",2,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":174,"minAge":17,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":182,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":4},"100509848","side-effects-screening-and-early-intervention-to-impact-in-quality-of-life-of-gynaecological-cancer-patients-100509848","NCT05918770","Side Effects Screening and Early Intervention to Impact in Quality of Life of Gynaecological Cancer Patients","Telemedicine-guided Patients Reported Outcome Measures (PROMs): Side Effects Screening and Early Intervention to Impact in Quality of Life of Gynaecological Cancer Patients","HALIS","Inclusion Criteria:\n\n* Women aged ≥18 diagnosed with ovarian, tubal and primary peritoneal, cervical and endometrial cancer who are candidates for surgery during the study period.\n\nExclusion Criteria:\n\n* Patients unable to complete by themselves the screening questionnaires included.","FEMALE",{"count":176,"type":21},168,[24],"The goal of this randomized study is to assess the impact on self-perceived quality of life (QoL) of systematic screening and early treatment of aftereffects in patients with gynaecological cancers. The main question it aims to answer is if systematic screening with validated questionaries (see in detailed description), diagnosis and early treatment of lower-limb lymphoedema, anxiety-depression, sexual dysfunction and sarcopenia-malnutrition all have a positive impact on the self-perceived QoL by gynaecological cancer patients. Participants will access the screening questionnaires and QoL questionaries on a free online app on their mobile devices. In the experimental group, in case of positive screening, patients will be referred to specialised care to early treatment of the aftereffects. Researchers will compare this group with standard usual care (opportunistic treatment) to see if systematic screening and early treatment lead to a better QoL.",[39,180,27,181],"Gynaecological Cancer","Sexual Dysfunction",[183,184],"quality of life","Gynaecological cancer","2023-06-23",{"date":187,"type":44},"2023-06-26",{"date":189,"type":21},"2023-09",{"date":191,"type":21},"2026-09",{"name":193,"class":51},"Hospital Universitario 12 de Octubre"]